Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19

Sponsor
Wake Forest University Health Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT04547283
Collaborator
(none)
40
1
2
3.5
11.3

Study Details

Study Description

Brief Summary

This study aims to determine if a strategy of recommending prone (on stomach) positioning of patients positive or suspected positive for coronavirus disease 2019 (COVID-19) requiring supplemental oxygen, but not mechanically ventilated, Is feasible in the inpatient setting. This study will be performed as a pragmatic pilot clinical trial to gain information relevant to the future conduct of a larger trial.

Condition or Disease Intervention/Treatment Phase
  • Other: Usual Care
  • Other: APPS
N/A

Detailed Description

Severe acute respiratory syndrome coronavirus-2, SARS-CoV-2, the virus causing coronavirus disease 2019 (COVID-19) pandemic, has rapidly led to significant morbidity and mortality worldwide, primarily through lower respiratory tract involvement progressing from hypoxemia to acute respiratory distress syndrome. Novel approaches to improving oxygenation are urgently needed to limit aerosolization concerns and resource scarcity associated with intubation and, to a lesser extent, other forms of advanced respiratory support.

Prone positioning in mechanically ventilated patients with hypoxemic respiratory failure has been associated with improvement in oxygenation and mortality in patients with acute respiratory distress syndrome (ARDS). The prone position appears to provide more uniform lung perfusion, shifting ventilation to well-perfused lung segments and recruitment of dependent atelectatic regions of lung. Physiological alterations associated with the prone position would foreseeably also apply to spontaneously breathing patients and evidence from small observational studies suggests that prone positioning in non-intubated patients is feasible associated with improvement in oxygenation. However, it remains unknown if a prone ventilation strategy is truly beneficial for non-intubated hypoxic Covid-19 patients, and this question has stimulated interest in the conduct of rigorous randomized controlled trials (RCT).

However, the awake prone strategy is a complex medical intervention with multiple implementation nuances such as adoption, feasibility, and tolerability that may affect successful conduct of a definitive RCT. In order to increase the likelihood of a successful future RCT, the investigators will conduct the APPS pilot study. The overall aim of the APPS pilot trial was to assess feasibility and important contextual factors for a large RCT to compare the clinical effectiveness of an Awake-Prone Positioning Strategy (APPS) for respiratory support versus usual care alone for hypoxic adults with Covid-19.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Clinicians were unblinded to treatment allocation and enrolled patients were considered unblinded. Clinical and safety outcomes were collected from the electronic health record by study investigators blinded to treatment assignment.
Primary Purpose:
Treatment
Official Title:
Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19: A Pilot Randomized Controlled Trial
Actual Study Start Date :
Jun 14, 2020
Actual Primary Completion Date :
Sep 20, 2020
Actual Study Completion Date :
Sep 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Usual Care

Participants randomized to this arm will remain in their clinician's team standard practice and their natural choice of position, which is anticipated to favor a supine (rather than prone) position.

Other: Usual Care
No clinical team recommendation, patients will remain in their natural choice of position

Experimental: Awake-Prone Positioning Strategy

Participants randomized to this arm will receive guidance from their Inpatient treatment team to assume the prone position for as much time as is tolerable during hospitalization.

Other: APPS
Clinical team guidance on prone positioning of patients

Outcome Measures

Primary Outcome Measures

  1. Average S/F ratio [48 hours from eligibility]

    Average oxygen saturation to fraction of inspired oxygen ratio

  2. Time spent with S/F ratio < 315 [48 hours from eligibility]

    Time spent with oxygenation saturation to fraction of inspired oxygen ratio less than 315

Secondary Outcome Measures

  1. Highest oxygen support [48 hours from eligibility]

    Highest level of supplemental oxygen required

  2. Number of patients requiring ICU admission during study period [48 hours from eligibility]

    Number of patients requiring ICU admission during study period

  3. Number of patients requiring ICU admission during hospitalization [through study completion, Up to 30 days]

    Number of patients requiring ICU admission during hospitalization

  4. Number of patients experiencing who die prior to discharge [through study completion, Up to 30 days]

    Number of patients who die prior to hospital discharge

  5. Number of patients requiring intubation [48 hours From eligibility]

    Number of patients requiring intubation

  6. Hospital length of stay [through study completion, Up to 30 days]

    Number of days from hospital admission to discharge

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • hospitalized patients with positive COVID testing during hospitalization or 7 days prior OR Hospitalized with suspected COVID pneumonia

  • room air oxygen saturation <93% or oxygen requirement > or equal to 3 Liters per minute

Exclusion Criteria:
  • unable to turn self, spinal instability, facial or pelvic fractures, open chest or open abdomen, altered mental status, anticipated difficult airway, show signs of respiratory fatigue, or receiving end-of-life care

Contacts and Locations

Locations

Site City State Country Postal Code
1 Carolinas Medical Center Charlotte North Carolina United States 28203

Sponsors and Collaborators

  • Wake Forest University Health Sciences

Investigators

  • Principal Investigator: Stephanie Taylor, MD, Wake Forest University Health Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Wake Forest University Health Sciences
ClinicalTrials.gov Identifier:
NCT04547283
Other Study ID Numbers:
  • 06-20-03E
First Posted:
Sep 14, 2020
Last Update Posted:
Apr 21, 2022
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 21, 2022